| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 18, 2025 | Karuna head, Teva alums meet minds to launch schizophrenia-focused biotech Syremis with $165M series A | A new mental health-driven biotech has arrived in Syremis Therapeutics. Co-founded by the mind behind Karuna Therapeutics and its novel schizophrenia treatment Cobenfy, the company has officially launched its mission to advance innovative t... |
| Jul 29, 2025 | BMS hands 5 autoimmune drugs to new spinout backed by $300M in Bain-led funding | Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain Capital-led financing as part of the Big Pharma’s ambitious cost-cutting drive.
The new biotech, which has yet to be name... |
| Jun 3, 2025 | The Clash Over Mascots: A Battle for Identity and Funding in New York | In the heart of New York, a storm brews over school mascots. The clash is not just about names and images; it’s a battle for identity, history, and funding. The recent visit by U.S. Secretary of Education Linda McMahon to Massapequa High Sc... |
| Jun 1, 2025 | S&P 500 posts modest gain to start June as investors shrug off global trade tensions: Live updates | Stocks rose on Monday, the first trading day of June, as Wall Street shook off increasing tensions in global trade.
The S&P 500 climbed 0.41% to close at 5,935.94, while the Nasdaq Composite advanced 0.67% and ended at 19,242.61. The Do... |
| May 6, 2025 | Bristol Myers to invest $40 billion in the US over 5 years | Bristol Myers to invest $40 billion in the US over 5 years
By ReutersMay 5, 202510:37 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Test tubes are seen in front of a displayed Bristol Myers Sq... |
| Jan 26, 2024 | Eli Lilly overtakes Tesla in market value | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with a look at a biotech rarity, a milestone on Wall Street, and pharma’s latest run-in... |
| Dec 26, 2023 | Bristol Myers will pay $4.1 billion for cancer startup RayzeBio | Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.
RayzeBio, which raised about $350 million in a September initial p... |
| Nov 20, 2023 | Merck cough drug doesn’t pass panel scrutiny | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s li... |
| Apr 27, 2023 | CAR T Therapy Dramatically Reduces Risk Of Relapse For Multiple Myeloma | Multiple myeloma is a cancer of the plasma cells. Carvykti, a CAR T therapy by Johnson & Johnson and ... [+] Legend Biotech, targets an antigen called BCMA found on the plasma cell surface and yields promising clinical results. Legend B... |
| Oct 18, 2022 | Johnson & Johnson Isn’t Rushing Into M&A | Most big pharma companies are moving with urgency to make acquisitions these days. The industry is sitting on a pile of cash from Covid-19 products, and many top companies need to replenish their pipelines as blockbuster drugs face generic ... |
| Sep 13, 2022 | Nimbus Therapeutics secures $125M in financing for clinical programs | Nimbus Therapeutics, a developer of medicines through computational drug discovery, announced Monday that it has closed $125 million in private financing.
Bain Capital Life Sciences and SV Health Investors led the funding round. The company... |
| Sep 12, 2022 | Bristol Myers Stock Jumps as U.S. Approves Psoriasis Drug. What It Means for the Sector. | Monday brought a seismic rearrangement in the competition among biopharma firms to sell high-priced psoriasis treatments, a category that has been a reliable source of blockbuster drugs for the sector.
Late Friday, Bristol Myers Squibb (tic... |
| Jul 27, 2022 | Bristol Myers Stock Drops After ‘Fairly Uninspiring’ Earnings Beat | The pharmaceutical firm Bristol Myers Squibb announced second-quarter earnings early Wednesday that beat Wall Street expectations. The stock, however, was falling in premarket trading after the company issued its report.
Bristol’s (ticker: ... |
| Jul 7, 2022 | Novo Nordisk workers in Korea protest after breakdown in salary and perks negotiations — report | In a pitched battle against Merck’s Keytruda, Bristol Myers Squibb’s immunotherapy headliner Opdivo landed a major salvo with a groundbreaking FDA approval for certain lung cancer patients back in 2018. Since that nod, however, Opdivo has t... |
| Jun 1, 2022 | Trailing AstraZeneca in lupus, Bristol Myers looks to push TYK2 drug into PhIII trials | In the past year, AstraZeneca has won US and EU approvals for its lupus antibody Saphnelo, which became the first new lupus drug to get approved since GSK’s Benlysta in 2011.
Lagging behind, Bristol Myers Squibb has also been... |
| Apr 29, 2022 | Bristol Beats Earnings Expectations, But Cuts Guidance | Bristol Myers Squibb lowered its forecast for earnings, sending the stock lower even though its financial results slightly beat Wall Street’s expectations.
The report came the morning after the company announced that the Food and Drug Admin... |
| Mar 25, 2022 | Bristol Myers' hope for a third Reblozyl OK delayed by three months | Bristol Myers Squibb was supposed to find out by this Sunday if the FDA was OK with a third approval for its Celgene-acquired, Acceleron-partnered anemia drug Reblozyl.
But “a major amendment” is putting a bump in those plans.
... |
| Feb 4, 2022 | Bristol Stock Inches Up After Earnings. It’s Beating the Market in 2022. | Bristol Myers Squibb reported financial results that just edged past Wall Street expectations, sending shares up slightly in premarket trading.
Bristol (ticker: BMY) reported non-GAAP earnings of $1.83 per share for the fourth quarter of 20... |
| Jan 20, 2022 | Bristol Myers Squibb : Receives Approval for Abecma (idecabtagene vicleucel), the First CAR T Therapy Approved for the Treatment of Multiple Myeloma in Japan | TOKYO, January 20, 2022 -- Bristol-Myers Squibb K.K. today announced that Japan's Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CA... |
| Jan 19, 2022 | Almost three years after whiffing in a confirmatory study, Merck touts new data for Keytruda in HCC | Keytruda’s accelerated approval in a common form of liver cancer looked shaky after the drug failed on two survival measures in a confirmatory study almost three years ago. Now Merck’s touting what could be a confirmat... |
| Jan 10, 2022 | What’s Happening With Bristol Myers Squibb Stock? | UKRAINE - 2021/05/24: In this photo illustration Bristol Myers Squibb logo seen displayed on a ... [+] smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images |
| Nov 29, 2021 | Like the flu vaccine every year, the FDA could move quickly on a variant-targeted Covid vaccine | After a second look, Merck says that its big breakthrough on the Covid front doesn’t look so good. An FDA adcomm of outside experts will take a look at the numbers on Tuesday and most likely recommend an EUA restricted to certain groups of ... |
| Nov 29, 2021 | Like the flu vaccine every year, the FDA could move quickly on a variant-targeted Covid vaccine | In the same way that the FDA signs off on flu vaccines every year without requiring large clinical trials to measure their efficacy, the FDA may employ a similar strategy in authorizing variant-focused versions of the ... |
| Nov 29, 2021 | Amid JAK debacle, Bristol Myers settles in for FDA's long review of potential first TYK2 drug | Bristol Myers Squibb has $4 billion hopes for its late-stage TYK2 inhibitor deucravacitinib, but the FDA’s recent negative review for the JAK inhibitor class has dampened hopes somewhat. Now, the agency will get its first good... |
| Nov 16, 2021 | Covid-19 roundup: Pfizer licenses its pill to the Medicines Patent Pool; NYC joins states in authorizing boosters for all adults ahead of FDA | When Google and a University of Washington lab released open source software last summer that could predict the structure of proteins with unprecedented accuracy, scientists almost universally hailed it as a breakthrough that could rapidly ... |
| Nov 16, 2021 | In quest to eliminate tropical diseases, Merck KGaA will submit anti-worming drug for approval in young children | Viatris (formerly known as Mylan and Pfizer’s Upjohn) on Tuesday opened up on the pricing of its interchangeable biosimilar for the insulin Lantus, saying the list price would be set at about $400 for a package of five 3 mL pens, which is a... |
| Nov 16, 2021 | In quest to eliminate tropical diseases, Merck KGaA will submit anti-worming drug for approval in young children | For as long as there have been HIV medicines, the only options for patients have been daily pills — until this year that is. GlaxoSmithKline’s ViiV Healthcare approval for long-acting injectable Cabenuva in January marked a sudden change.
I... |
| Nov 16, 2021 | Covid-19 roundup: Pfizer licenses its pill to the Medicines Patent Pool; NYC joins states in authorizing boosters for all adults ahead of FDA | A few weeks after Jennifer Doudna introduced CRISPR/Cas9 genome editing to the world, one of her old students decided to take the central part of the biology-altering invention and kill it.
CRISPR/Cas9, as the name implies, is a two-part sy... |
| Nov 16, 2021 | Covid-19 roundup: Pfizer licenses its pill to the Medicines Patent Pool; NYC joins states in authorizing boosters for all adults ahead of FDA | For the first time since the pandemic began, BioNTech CEO Uğur Şahin made his way to the US, this time for a cancer drug conference in Washington, DC, last week. Prior to presenting his company’s poster on early, promising data for its CLDN... |
| Nov 16, 2021 | Covid-19 roundup: Pfizer licenses its pill to the Medicines Patent Pool; NYC joins states in authorizing boosters for all adults ahead of FDA | Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up... |
| Nov 16, 2021 | CBC Group establishes new fund to meet China's booming life sciences real estate demand | Demand for life science real estate is surging in China — and one of Asia’s largest investment groups is rising to the call.
Roger Perlmutter
CBC Group — the startup engine that recently lured in Merck’s former R&D chie... |
| Nov 16, 2021 | CRISPR, ViaCyte beat Vertex to the clinic with diabetes cell therapy that evades the immune system | Can injecting messenger RNA directly into the heart of patients who’ve experienced heart failure help repair the organ? More than three years after AstraZeneca and Moderna launched a first-of-its-kind Phase II trial to test the idea, the pa... |
| Nov 16, 2021 | Covid-19 roundup: Pfizer licenses its pill to the Medicines Patent Pool; NYC joins states in authorizing boosters for all adults ahead of FDA | Following a similar deal forged by Merck for its Covid-19 drug molnupiravir, Pfizer on Tuesday agreed to allow the UN-backed Medicines Patent Pool to license the company’s potential treatment Paxlovid to make it more read... |
| Nov 16, 2021 | Covid-19 roundup: Pfizer licenses its pill to the Medicines Patent Pool; NYC joins states in authorizing boosters for all adults ahead of FDA | Contract manufacturing for domestic companies until recently didn’t exist in China, thanks to some regulatory restrictions that required developers to be in charge of their own manufacturing process. Now, the young business model is being t... |
| Nov 16, 2021 | Covid-19 roundup: Pfizer licenses its pill to the Medicines Patent Pool; NYC joins states in authorizing boosters for all adults ahead of FDA | Contract manufacturers are having a moment, and it hasn’t gone unnoticed by the folks at CPhI.
The organization’s annual report found that CMOs will account for four of the five top companies by manufacturing capacity in 2025. Dawn Ecker, a... |
| Nov 16, 2021 | Covid-19 roundup: Pfizer licenses its pill to the Medicines Patent Pool; NYC joins states in authorizing boosters for all adults ahead of FDA | When you’re heading up a fledgling biotech out to make a name for yourself in the middle of a wild industry boom, there’s one sure way to differentiate yourself that’s bound to attract universal nods.
It doesn’t involve lots of money — plen... |
| Nov 16, 2021 | CRISPR, ViaCyte beat Vertex to the clinic with diabetes cell therapy that evades the immune system | The race to develop a cell therapy for type 1 diabetes is heating up, and the team at ViaCyte and CRISPR Therapeutics appears to have pulled ahead by a hair.
ViaCyte announced Tuesday it’s putting a new therapy in the cli... |
| Nov 16, 2021 | Covid-19 roundup: Pfizer licenses its pill to the Medicines Patent Pool; NYC joins states in authorizing boosters for all adults ahead of FDA | CPhI week is always a time each year to reflect on the manufacturing world writ large, and this year’s event is no different.
Normally, Endpoints News would be on site this week in Milan — we hired dedicated manufacturing reporter Josh Sull... |
| Nov 16, 2021 | Covid-19 roundup: Pfizer licenses its pill to the Medicines Patent Pool; NYC joins states in authorizing boosters for all adults ahead of FDA | Not five months after launching with an old Eli Lilly asset, Acrivon Therapeutics is already upping the ante.
The Cambridge, MA-based biotech pulled in $100 million in a new Series B, aiming to further advance its lead asset and companion p... |
| Nov 16, 2021 | In quest to eliminate tropical diseases, Merck KGaA will submit anti-worming drug for approval in young children | In the early days of the pandemic, there was a mad scramble for information. What was a coronavirus, how likely was a vaccine and how soon could it be developed?
At Johnson & Johnson, where Janssen scientists were already at work on vac... |
| Nov 16, 2021 | UK's Synthace raises $35M in Series C; Oncology and inflammatory disease biotech Deka hauls in $20M Series A | UK-based AI-assisted R&D biotech Synthace just wrapped up a Series C round, bringing in $35 million.
Per a company statement this morning, the investment will fuel commercial and go-to-market (GTM) growth as Synthace co... |
| Nov 16, 2021 | UPDATED: ICER finds unsubstantiated drug price increases cost US $1.67B in 2020, but overall net increases lower than years past | The Institute for Clinical and Economic Review on Tuesday morning released its latest on “unsupported” drug price increases for seven top treatments, and how even after rebates and other concessions, these increases... |
| Nov 16, 2021 | Covid-19 roundup: Pfizer licenses its pill to the Medicines Patent Pool; NYC joins states in authorizing boosters for all adults ahead of FDA | Late last month, Cortexyme announced a subset of patients saw their cognitive decline slow while taking the high dose of the company’s experimental Alzheimer’s drug, offering some support for an outside-the-box approach to treating the dise... |
| Nov 16, 2021 | In quest to eliminate tropical diseases, Merck KGaA will submit anti-worming drug for approval in young children | Bristol Myers Squibb is looking to shine a light on the rarely diagnosed heart condition hypertrophic cardiomyopathy (HCM) as it awaits an FDA decision on a proposed drug to treat it.
The unbranded “Could It Be HCM?” campaign that launched ... |
| Nov 16, 2021 | Covid-19 roundup: Pfizer licenses its pill to the Medicines Patent Pool; NYC joins states in authorizing boosters for all adults ahead of FDA | The rejection of its PD-1 inhibitor, retifanlimab, was never going to be the end of Incyte’s checkpoint story. Not only was the biotech holding out hope of changing the FDA’s mind and testing the cancer drug in multiple combinations, it als... |
| Nov 16, 2021 | A Czech biotech bets big on rising ADC player LegoChem as part of licensing pact aimed at solid tumors | Czech biotech Sotio will pay $29.5 million upfront with a potential $1.03 billion in downstream milestones to license five antibody-drug conjugate programs from LegoChem Biosciences, the partners announced Tuesday.
Detail... |
| Nov 16, 2021 | Covid-19 roundup: Pfizer licenses its pill to the Medicines Patent Pool; NYC joins states in authorizing boosters for all adults ahead of FDA | Novartis bet large on The Medicines Company’s RNAi heart drug inclisiran, expecting to shake up that segment of the market with a swift US approval. But after getting stiff-armed by the FDA last year, the pharma giant’s now releasing more p... |
| Nov 16, 2021 | Covid-19 roundup: Pfizer licenses its pill to the Medicines Patent Pool; NYC joins states in authorizing boosters for all adults ahead of FDA | When Acelyrin closed its Series A late last year, it was met with little fanfare. The biotech had only two employees, the former R&D chief and CBO of Horizon Therapeutics, and didn’t even disclose the size of the raise. Westlake Village... |
| Nov 15, 2021 | Cassava being investigated by unnamed 'government agencies'; Rocket Pharma gives updated data on Danon disease | Cassava Sciences likes to fight fire with fire, with CEO Remi Barbier calling a citizen petition to halt development on its lead drug a “short attack” in September. But the noise surrounding the saga has apparently dra... |
| Nov 15, 2021 | Former Blueprint vets take their new biotech out of stealth, with STAT3 in their sights | A new biotech going after STAT mutations through a previously undruggable target emerged from stealth and secured its first fundraise Monday, introducing its freshly minted CEO in the process.
Recludix Pharma, a San Diego... |
| Nov 15, 2021 | UPDATED: As Ginkgo looks to clear its name, the feds have come sniffing around on the heels of short sell report | A month and a half after a short sell attack nearly brought Ginkgo Bioworks’ newly public shares to its knees, the company on Monday took its largest step to date toward clearing its name. But it also revealed it’s currently ... |
| Nov 15, 2021 | Medidata Solutions co-founder Glen de Vries dies in plane crash | Even celebrities are piqued by biotech these days. For Bono and The Edge, it appears they’ve found what they’re looking for — and they’re willing to put their money on it.
The Irish peptide biotech Nuritas closed a $45 million Series B, an ... |
| Nov 14, 2021 | J&J looks to toss its SGLT2 hat in the ring for two types of heart failure | In the last year, two SGLT2 inhibitors — initially developed to treat diabetes — have snagged approvals in the heart failure space. Now Johnson & Johnson is jumping on the bandwagon, reading out positive Phase III resu... |
| Nov 14, 2021 | Eli Lilly and Boehringer Ingelheim set their sights on acute heart failure with new Jardiance data | A few months after Eli Lilly and Boehringer Ingelheim broke into the chronic heart failure space with their SGLT2 inhibitor Jardiance, the partners are already plotting an expansion into acute heart failure — and on Sunday,... |
| Nov 12, 2021 | Appili's Covid-19 oral antiviral fails PhIII trial; Oncology biotech Ankyra raises $45M in Series B | Appili Therapeutics’s investigational oral antiviral Avigan/Reeqonus failed in a Phase III trial, the biotech said in a statement this morning.
The Nova Scotia biotech’s PRESECO trial, which enrolled more than 1,200 pati... |
| Nov 12, 2021 | A couple months ahead of its PDUFA date, Bristol Myers rolls out long-term data for mavacamten | It’s almost time for the FDA to make a decision on mavacamten, the myosin inhibitor at the center of Bristol Myers Squibb’s $13 billion MyoKardia buyout. With a Jan. 28 PDUFA date looming, the pharma giant is now taking the ... |
| Nov 12, 2021 | UPDATED: J&J sets out to split the world's largest healthcare conglomerate, hiving off the consumer division | Back at the beginning of 2020, Genentech vet Blake Wise jumped to a startup in the Bay Area called Novome, joining at the same time a syndicate came together to offer a $33 million launch round for a platform biotech out to colonize the gut... |
| Nov 12, 2021 | UPDATED: J&J sets out to split the world's largest healthcare conglomerate, hiving off the consumer division | Five months after ejecting out of the mother ship at Merck, the women’s health experts at Organon have racked up another deal, this time buying up a small biotech advancing an experimental therapy for endometriosis.
Organon put out word Thu... |
| Nov 12, 2021 | CytoImmune CEO breaks down her 3 'pillars' of success; Former Novartis, Gilead exec Alessandro Riva to lead an ultra low-profile cell therapy outfit | Christina Coughlin
Christina Coughlin loves cell therapy — pretty much defining her career since her postdoc days with Carl June in Pennsylvania.
Now as the new head honcho at CytoImmune as of Wednesday, the first-time CEO ... |
| Nov 11, 2021 | A better way to control where drugs go? Investors bet on small biotech's mission to 'click' together cancer meds | While José Mejía Oneto was an orthopedic surgery resident at UC Davis, he learned an intriguing yet frustrating fact: Only small amounts of a drug — in some cases just 1% or 2% of what’s administered — actually make it to ... |
| Nov 11, 2021 | List Bio to join Indiana biotech community with $125M CMO investment, 210 new hires | An expansion is coming to the Fishers Life Science and Innovation Park, and with it, plans to hire another 210 employees by the end of 2023.
List Biotherapeutics will pump $125 million into the project, establishing a 1... |
| Nov 11, 2021 | Roche, AC Immune attempt to flesh out anti-tau Alzheimer's data, but the forecast remains cloudy | AC Immune reported full data on its leading anti-tau antibody for mild-to-moderate Alzheimer’s on Wednesday afternoon, and the complete picture came in decidedly mixed.
Building on previously released results from Au... |
| Nov 11, 2021 | Too much iron? Pharmacosmos is betting $225M on a new potential solution for that | Danish biotech Pharmacosmos has come a long way since it was launched back in 1965 as an active pharmaceutical ingredient (API) manufacturer. While it’s still in the same family, the company now has three drugs approved... |
| Nov 11, 2021 | Fujifilm boosts manufacturing capacity alongside R&D; Baxter International will invest $100M in BioPharma Solutions | Fujifilm Irvine Scientific is expanding an R&D center in California, and it’s boosting its manufacturing along with it.
The company announced Wednesday that it would expand its Armstrong R&D Center of Excell... |
| Nov 11, 2021 | Kaléo to pay out more than $12M in false claims case regarding high-priced version of cheap opioid overdose antidote; UroGen gets ready to start PhIII cancer trial | Virginia pharma Kaléo has agreed to pay the United States $12.7 million to resolve accusations that the pharma caused the submission of false claims for Evzio, an injectable form of naloxone hydrochloride indicated for use... |
| Nov 11, 2021 | Genenta is attempting a rare biotech leap from Milan to Wall Street | Pierluigi Paracchi, CEO and one of the trio of leaders running gene therapy biotech Genenta, has frequently lamented the absence of Italian biotechs on Nasdaq. And now, he’s taking his Milan-based company and jumping out ... |
| Nov 10, 2021 | Bill and Melinda Gates Foundation backs little-known biotech going after Pfizer, Merck on pneumococcal vaccine | The Bill and Gates Melinda Foundation has raised big money over its lifetime to support medicines for poorer countries, and it announced its latest investment on Wednesday.
Inventprise, a biotech located in the Seattle s... |
| Nov 10, 2021 | Ligand to split in half, spinning OmniAb platform into its own company | It’s been six years since Ligand Pharmaceuticals plumped down $178 million for OMT and its antibody discovery platform OmniAb. Now, with a slate of big-name partners, it’s time for the technology to take on a new life as its... |
| Nov 10, 2021 | CPhI: Industry execs ready to put a difficult couple years behind them as pharma confidence looks bullish | As vendors from around the world gather at the CPhI Global conference this week in Milan, confidence in the industry’s future looks extremely bullish heading into 2022, according to the CPhI Pharma Index.
The index serv... |
| Nov 10, 2021 | EQT Group acquires VC firm in $500M+ deal; Sanofi selects IPO leaders for 2022 API spinout — report | Private investment group EQT announced an agreement this morning to buy out Life Science Partners, a European VC firm with more than $2.5 billion under management.
While details are not complete, EQT agreed to $520 million ... |
| Nov 8, 2021 | Bristol Myers adds to neoadjuvant win for Opdivo in lung cancer, escalating early cancer showdown with Merck | Bristol Myers Squibb and Merck are locked in a heated race to bring their blockbuster PD-(L)1 drugs into early cancer patients as part of potentially curative combinations. The approvals have been coming fast and heavy, a... |
| Oct 27, 2021 | Third Quarter 2021 Earnings Release | Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
Reports Third Quarter Revenues of $11.6 Billion, an Increase of 10% YoY
Posts Third Quarter Earnings Per Share of $0.69 and Non-GAAP EPS of $2.00
Advances Product Pipelin... |
| Oct 21, 2021 | Exclusive: Athira CEO Leen Kawas resigns after investigation finds she manipulated data | Bristol Myers Squibb’s deucravacitinib, seeking to become the first TYK2 drug approved, flopped a key Phase II test in ulcerative colitis, failing to spur clinical remission at three months and missing key secondary endpoints at an interim ... |
| Aug 2, 2021 | Bristol Myers pulls lymphoma indication for Istodax after confirmatory trial falls flat | Amid an industrywide review of cancer drugs with accelerated approval, Bristol Myers Squibb had to make the tough call last month to yank an approval for leading I/O drug Opdivo after flopping a confirmatory study. Now... |
| Jul 16, 2021 | Pfizer settles EpiPen price hike lawsuits for $345M | As the feather in New York’s life sciences cap, Regeneron has maintained a warm relationship with the state’s foremost political family, the Cuomos. Legendary Gov. Mario Cuomo had a hand in getting Regeneron on its feet early, and now his s... |
| Jul 16, 2021 | Bristol Myers Squibb takes another late-stage loss for Opdivo-Yervoy combo in head and neck cancer | Bristol Myers Squibb has worked overtime to hunt down an edge for its PD-(L)1 blocker Opdivo over rival Keytruda from Merck, including taking a bold combo strategy with CTLA4 inhibitor Yervoy. But in head and neck cancer,... |
| Jul 16, 2021 | Bristol Myers Squibb takes another late-stage loss for Opdivo-Yervoy combo in head and neck cancer | The folks at contract manufacturer AMRI were looking to transform their business into a disruptor. They first started with a name change — AMRI is now Curia — and then locked down two acquisitions they hope will take the company into the fu... |
| Jul 16, 2021 | Alexion touts new PhIII data of Soliris successor as planned AstraZeneca takeover looms | A little less than a week before AstraZeneca’s takeover of Alexion is expected to be completed, the rare disease biotech offered up a cut of data for its Soliris successor.
In a Phase III study for Ultomiris looking at adults... |
| Jul 16, 2021 | Pfizer settles EpiPen price hike lawsuits for $345M | The FDA’s Cardiovascular and Renal Drugs Advisory Committee on Thursday afternoon voted 12 to 2 against approving AstraZeneca and FibroGen’s anemia drug roxadustat as a treatment of anemia due to chronic kidney disease in adult patients on ... |
| Jul 16, 2021 | Pfizer settles EpiPen price hike lawsuits for $345M | Pfizer has agreed to pay $345 million as part of a settlement related to a 5-year-old lawsuit over the company’s price hikes on the lifesaving EpiPen.
Plaintiffs across the country raised concerns over the price of the autoin... |
| Jun 14, 2021 | Bristol Myers Squibb Stock Remains Undervalued After Positive Data From Clinical Trials | UKRAINE - 2021/04/19: In this photo illustration, Bristol-Myers Squibb Company logo seen displayed ... [+] on a smartphone with the stock market information of Bristol-Myers Squibb Company in the background. (Photo Illustration by Igor Golo... |
| May 25, 2021 | BRISTOL-MYERS SQUIBB COMPANY
Bristol Myers Squibb : Foundation Announces First Global Cancer Disparities Grants in Brazil | Four Projects in Brazil Receive Inaugural Grants to Improve Delivery of Care for Lung Cancer and Melanoma Patients
(New York, May 25, 2021) -- The Bristol Myers Squibb Foundation has launched a new initiative in Brazil, awarding four grants... |
| Mar 19, 2021 | FDA accepts Bristol Myers' pitch for former MyoKardia drug; Clovis' Rubraca aces advanced ovarian cancer study | The program at the centerpiece of Bristol Myers Squibb’s buyout of MyoKardia just got one step closer to gaining potential FDA approval.
BMS announced Friday that the agency has accepted its NDA pitch, scheduling a Jan. 28... |
| Feb 23, 2021 | Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way | We should know on Friday whether J&J will get the green light to start using its vaccine in the US as an expert panel does its review ahead of a quick follow-up from regulators. Right now, it’s an odds-on favorite for an approval, and t... |
| Feb 23, 2021 | Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way | After a long-awaited approval for its CD19 targeting CAR-T liso-cel, Bristol Myers Squibb is gearing up for the looming review of another cell therapy in its pipeline, ide-cel. Taking not one but two CAR-Ts to market — and p... |
| Feb 22, 2021 | AstraZeneca pulls Imfinzi in bladder cancer, nearly one year after Phase 3 miss | The withdrawal does not affect Imfinzi’s marketing outside of the U.S., nor does it have any bearing on the drug’s FDA approvals in lung cancer.
Imfinzi is a so-called “checkpoint inhibitor,” a type of cancer immunotherapy that works by blo... |
| Feb 13, 2021 | Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med | Bristol Myers Squibb has seen setback after setback for its chances to bring immuno-oncology blockbuster Opdivo into newly diagnosed brain cancer patients — a sort of holy grail for the field. Despite holding a slim hope Opdivo would turn a... |
| Feb 5, 2021 | Bristol Myers lymphoma therapy acquired in Celgene deal wins FDA nod | The FDA approved the therapy, lisocabtagene maraleucel, as a treatment for adults who have certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL), whose cancer has not responded to or has relapsed after at le... |
| Feb 4, 2021 | FDA cites litany of errors at Lonza Houston plant at the center of Bristol Myers CVR debacle | Investors’ somewhat longshot bet on a $9 CVR tied to Bristol Myers Squibb’s acquisition of Celgene came to a screeching halt last month after the FDA took too long to decide on CAR-T candidate liso-cel. One of the potential ... |
| Feb 4, 2021 | Sana Bio soars in stock market debut, raising $588M for cell & gene therapies | Sana priced its upsized offering of 23.5 million shares at $25 apiece. That’s significantly more than the biotech initially planned. When it set the terms of the offering last week, it projected selling 15 million shares in the range of $20... |
| Jan 20, 2021 | Bristol Myers Squibb gets review date for Opdivo combo in gastric cancer, looking to overturn Keytruda's 3-year lead | The past two months have been tough for Bristol Myers Squibb and its checkpoint inhibitor Opdivo after setbacks in lung and brain cancers. But in the battle against Merck’s Keytruda, any success matters — and now Bristol coul... |
| Nov 18, 2020 | Bristol Myers Squibb Foundation launches program to tackle diversity problem in clinical trials | Over the last several months, the pandemic has amplified calls for more diverse clinical trials.
While minority populations are contracting Covid-19 at higher rates than white Americans, they are notably underrepre... |
| Nov 10, 2020 | Merck pulls the plug on a study evaluating blockbuster Keytruda with Yervoy for NSCLC | About a month ago, upon touting new oncology data, Merck reaffirmed its commitment to exploring new Keytruda combinations for lung cancer patients. The Big Pharma has now pulled the plug on one of those combinations, a... |
| Oct 20, 2020 | News briefing: Merck preps FDA pitch after adding more data on V114; Bristol Myers, Exelixis get quick review for cancer combo | Merck has new data out from two Phase III trials on its pneumococcal conjugate vaccine candidate covering 15 different serotypes.
The program, dubbed V114, was tested in the first study in healthy adults aged 50 or older, ... |
| Oct 5, 2020 | Opdivo/Yervoy combo flops again in melanoma, but Bristol Myers Squibb also has a new OK to celebrate | Bristol Myers Squibb’s Opdivo/Yervoy combo regimen has officially failed both co-primary endpoints in a trial testing it as an adjuvant therapy for melanoma.
Adding Yervoy, the CTLA4 inhibitor, to the PD-1 antibody ... |
| Jul 31, 2020 | Roche snags an FDA approval for an advanced melanoma drug cocktail — but it's up against some fierce competition | Roche’s PD-L1 inhibitor Tecentriq snagged an FDA approval to treat certain advanced melanoma patients in a three-drug cocktail, providing another option for patients with a typically poor prognosis.
In a Phase III IMspire... |
| Jul 30, 2020 | BMS, bluebird refile FDA approval application for CAR-T therapy in myeloma | Shares of bluebird rose 2.6% in after-hours trading on the Nasdaq following the news Wednesday. BMS’ shares also rose slightly on the New York Stock Exchange.
The companies had sought approval of the drug earlier this year, but they hit a r... |
| Jun 2, 2020 | Bristol Myers Squibb's just-launched MS drug Zeposia makes the cut in key ulcerative colitis trial | In March, Zeposia became the third oral S1P modulator to secure US approval for multiple sclerosis. Now, the drug has succeeded in a key ulcerative colitis study.
The immunomodulator, akin to others in its class, cont... |
| May 11, 2020 | BMS to pay bluebird $200M as companies rejigger myeloma CAR-T development partnership | BMS and bluebird will continue to share profits and losses on the CAR-Ts in the U.S. market, and bluebird is in the process of building a manufacturing plant for the therapy in Durham, North Carolina. The plant will manufacture lentiviral v... |
